67 research outputs found
Recovery of visual fields in brain-lesioned patients by reaction perimetry treatment
<p>Abstract</p> <p>Background</p> <p>The efficacy of treatment in hemianopic patients to restore missing vision is controversial. So far, successful techniques require laborious stimulus presentation or restrict improvements to selected visual field areas. Due to the large number of brain-damaged patients suffering from visual field defects, there is a need for an efficient automated treatment of the total visual field.</p> <p>Methods</p> <p>A customized treatment was developed for the reaction perimeter, permitting a time-saving adaptive-stimulus presentation under conditions of maximum attention. Twenty hemianopic patients, without visual neglect, were treated twice weekly for an average of 8.2 months starting 24.2 months after the insult. Each treatment session averaged 45 min in duration.</p> <p>Results</p> <p>In 17 out of 20 patients a significant and stable increase of the visual field size (average 11.3° ± 8.1) was observed as well as improvement of the detection rate in the defective visual field (average 18.6% ± 13.5). A two-factor cluster analysis demonstrated that binocular treatment was in general more effective in augmenting the visual detection rate than monocular. Four out of five patients with a visual field increase larger than 10° suffered from hemorrhage, whereas all seven patients with an increase of 5° or less suffered from infarction. Most patients reported that visual field restoration correlated with improvement of visual-related activities of daily living.</p> <p>Conclusion</p> <p>Rehabilitation treatment with the Lubeck Reaction Perimeter is a new and efficient method to restore part of the visual field in hemianopia. Since successful transfer of treatment effects to the occluded eye is achieved under monocular treatment conditions, it is hypothesized that the damaged visual cortex itself is the structure in which recovery takes place.</p
Using lithium as a neuroprotective agent in patients with cancer
Neurocognitive impairment is being increasingly recognized as an important issue in patients with cancer who develop cognitive difficulties either as part of direct or indirect involvement of the nervous system or as a consequence of either chemotherapy-related or radiotherapy-related complications. Brain radiotherapy in particular can lead to significant cognitive defects. Neurocognitive decline adversely affects quality of life, meaningful employment, and even simple daily activities. Neuroprotection may be a viable and realistic goal in preventing neurocognitive sequelae in these patients, especially in the setting of cranial irradiation. Lithium is an agent that has been in use for psychiatric disorders for decades, but recently there has been emerging evidence that it can have a neuroprotective effect.This review discusses neurocognitive impairment in patients with cancer and the potential for investigating the use of lithium as a neuroprotectant in such patients.<br /
Using lithium as a neuroprotective agent in patients with cancer
Neurocognitive impairment is being increasingly recognized as an important issue in patients with cancer who develop cognitive difficulties either as part of direct or indirect involvement of the nervous system or as a consequence of either chemotherapy-related or radiotherapy-related complications. Brain radiotherapy in particular can lead to significant cognitive defects. Neurocognitive decline adversely affects quality of life, meaningful employment, and even simple daily activities. Neuroprotection may be a viable and realistic goal in preventing neurocognitive sequelae in these patients, especially in the setting of cranial irradiation. Lithium is an agent that has been in use for psychiatric disorders for decades, but recently there has been emerging evidence that it can have a neuroprotective effect.This review discusses neurocognitive impairment in patients with cancer and the potential for investigating the use of lithium as a neuroprotectant in such patients.<br /
Integral strategy to supportive care in breast cancer survivors through occupational therapy and a m-health system: design of a randomized clinical trial
Background: Technological support using e-health mobile applications (m-health) is a promising strategy to improve
the adherence to healthy lifestyles in breast cancer survivors (excess in energy intake or low physical activity are
determinants of the risk of recurrence, second cancers and cancer mortality). Moreover, cancer rehabilitation
programs supervised by health professionals are needed due to the inherent characteristics of these breast cancer
patients. Our main objective is to compare the clinical efficacy of a m-health lifestyle intervention system alone versus
an integral strategy to improve Quality of Life in breast cancer survivors.
Methods: This therapeutic superiority study will use a two-arm, assessor blinded parallel RCT design. Women will be
eligible if: they are diagnosed of stage I, II or III-A breast cancer; are between 25 and 75 years old; have a Body Mass
Index > 25 kg/m2; they have basic ability to use mobile apps; they had completed adjuvant therapy except for
hormone therapy; and they have some functional shoulder limitations. Participants will be randomized to one of
the following groups: integral group will use a mobile application (BENECA APP) and will receive a face-to-face
rehabilitation (8-weeks); m-health group will use the BENECA app for 2-months and will received usual care
information. Study endpoints will be assessed after 8 weeks and 6 months. The primary outcome will be Quality
of Life measured by The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core
and breast module. The secondary outcomes: body composition; upper-body functionality (handgrip, Disability of the
Arm, Shoulder and Hand questionnaire, goniometry); cognitive function (Wechsler Adult Intelligence Scale, Trail Making
Test); anxiety and depression (Hospital Anxiety and Depression Scale); physical fitness (Short version of the Minnesota
Leisure Time Physical Activity Questionnaire, Self-Efficacy Scale for Physical Activity); accelerometry and lymphedema.
Discussion: This study has been designed to seek to address the new needs for support and treatment of breast cancer
survivors, reflecting the emerging need to merge new low cost treatment options with much-needed involvement of
health professionals in this type of patients.
Trial registration: ClinicalTrials.gov Identifier: NCT02817724 (date of registration: 22/06/2016).The study was funded by the Spanish Ministry of Economy and Competitiveness
(Plan Estatal de I + D + I 2013-2016), Fondo de Investigación Sanitaria del Instituto
de Salud Carlos III (PI14/01627), Fondos Estructurales de la Unión Europea (FEDER)
and by the Spanish Ministry of Education (FPU14/01069). This is part of a Ph.D.
Thesis conducted in the Clinical Medicine and Public Health Doctoral Studies of
the University of Granada, Spain
Can physical activity help to maintain cognitive functioning and psychosocial well-being among breast cancer patients treated with chemotherapy? A randomised controlled trial: study protocol
Background: Evidence suggests chemotherapy treatment for breast cancer is associated with side effects such as
cognitive impairment in domains of memory, attention, concentration and executive function. Cognitive impairments reported by patients have been associated with higher levels of emotional distress. To date, intervention studies to alleviate cognitive impairment associated with chemotherapy have focused on psycho-educational techniques or cognitive training. Studies have not yet considered physical activity as a potential for alleviating cognitive problems. Physical activity interventions are reported to be effective in alleviating emotional distress and fatigue in those with breast cancer. They have also been reported to improve cognitive functioning in the elderly, in those suffering with dementia and in children. We propose that physical activity could also help to alleviate cognitive impairments in women diagnosed with breast cancer. The study has been designed using a recently developed taxonomy of behaviour change techniques to reliably report the content of the intervention to allow future replication.
Method: This study will deliver a home-based moderate intensity walking intervention to women diagnosed with breast cancer mid-way through their chemotherapy treatment and will compare them to patients receiving usual care alone. The primary outcome measure for this intervention is changes in an objective measure of memory assessed using the Digit Span. Secondary outcome measures include: objective measures of executive function; attention; visual spatial skills; self report cognitive function; self-report fatigue; anxiety; depression; mood and self-esteem. As emotional distress has been associated with self-reporting of cognitive problems, this intervention will further test whether emotional distress mediates between the amount of walking undertaken during the
intervention period and levels of self-reported cognitive functioning.
Discussion: The development of an effective intervention for preventing difficulties in emotional and cognitive functioning of cancer patients’ post-treatment will help to guide health care professionals to improve patients’ overall quality of life. It will also provide direction for future research, ultimately to improve the day to day functioning of breast cancer survivors.
Trial Registration: Current Controlled Trials ISRCTN50709297.
Keywords: Intervention, Breast cancer, Chemotherapy, Physical activity, Exercise, Walking, Cognitive function,
Emotional distress, Psychosocial well-bein
- …